According to the press, US partner Johnson & Johnson (J&J) reported -14% lower sales of blood thinner Xarelto in Q4 18.
29 Jan 2019
The going gets tough(er)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The going gets tough(er)
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
29 Jan 2019 -
Author:
Martin Schnee -
Pages:
2
According to the press, US partner Johnson & Johnson (J&J) reported -14% lower sales of blood thinner Xarelto in Q4 18.